Domain Therapeutics S.A.

Domain Therapeutics S.A.

Domain Therapeutics S.A. was established in 2017 as a biopharmaceutical company headquartered in Vancouver, Canada, with operations also in Montreal and Strasbourg, France. The firm is known for its focus on G protein-coupled receptors (GPCRs), a class of drug targets that are implicated in a wide range of diseases. Its wealth origin is undisclosed, but the entity operates as a private company backed by institutional investors and grant funding. The company's investment strategy centers on discovering and developing small-molecule therapeutics, particularly in immuno-oncology and neurology. Its pipeline includes programs targeting adenosine A2A receptor in oncology and metabotropic glutamate receptors for neurological conditions. Domain Therapeutics has disclosed collaborations with academic institutions and contract research organizations, but its portfolio companies are internal programs rather than external investments. Domain Therapeutics maintains a small, specialized team of approximately 15–30 employees across its three locations. The firm has not publicly disclosed total funding or AUM, but it has completed Series A and later venture rounds, per public filings and government grants from French and Canadian agencies. No recent operational events have been publicized in the last 24 months. A structural differentiator is the firm's dual-geography footprint in both Canada and France, which allows it to access both North American and European funding streams, including public research grants. The company operates as a private biotech developing its own IP rather than as a fund investing in external startups, making it akin to a hybrid operating company with venture-like capital deployment.